DNAprint Genomics (DNAG)

[sam1933]

Ann,

-Biofrontera’s drug discovery and development projects combined with DNAPrint’s unique population genomics-based diagnostic tests ...
--------------

Biofrontera
Supervisory board
Richard Gabriel, BS, MBA, is CEO and President of DNAPrint genomics Inc. (USA). Prior to this, he held the same position at Calix Corporation, the parent company of PharmEco Laboratories, Inc.. Mr. Gabriel has years of experience consulting and managing joint venture and start-up companies, working in gene technology as well as in the chemical and pharmaceutical field, with particular expertise in GMP scale-up, manufacturing and compliance.

Drug Pipeline
Compound Status
BF-200 ALA Clinical Phase IIb/III for actinic keratosis and condyloma
BF-derm1 Clinical Phase II for antihistamine-refractory urticaria
BF-37 Phase II for atopic dermatitis
BF-1 In clinical development for migraine prophylaxis in Q4 2006
http://www.biofrontera.com/index.php?id=7


Biofrontera’s drug discovery and development projects will be combined with DNAPrint’s unique approach for the discovery of population genomics-based diagnostic tests for the improved selection of patient groups. Management expects this to facilitate the demonstration of drug efficacy and potential adverse events and accelerate selected drugs through the clinical trial process.
http://www.bio-pro.de/en/region/rhein/meldungen/00864/index.html
-----------------------

… The Wall Street Analyst Forum Presentation Transcript

***I should also point out that we, in the biotech industry, also spend a great deal of our time and effort in developing drugs in Europe and also doing our clinical trials in Europe. So, it kind of makes sense that if we are doing that in Europe, perhaps we should also consider being financed in Europe.
http://soundmoneytips.com/article/47832-dnaprint-genomics-the-wall-street-analyst-forum-presentation-transcript?page=4

sam